X4 Pharmaceuticals (XFOR) Change in Cash (2017 - 2026)

X4 Pharmaceuticals (XFOR) has reported Change in Cash for 10 consecutive years, with -$21.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Cash fell 2031.31% year-over-year to -$21.7 million; the trailing twelve-month figure through Jun 2026 stood at $155.7 million (up 244.24% YoY), and the FY2025 full-year result was $161.4 million, up 468.67% from the prior year.
• Change in Cash slipped to -$21.7 million in Q2 2026 per XFOR's latest filing, from -$365000.0 in the prior quarter.
• Across five years, Change in Cash topped out at $147.4 million in Q4 2025 and bottomed at -$49.8 million in Q3 2024.
• Historically, Change in Cash has averaged $6.3 million across 5 years, with a median of -$10.1 million in 2022.
• The sharpest annual moves came in 2022 and 2026: Change in Cash surged 677.28% in 2022, then tumbled 2031.31% in 2026.
• Over 5 years, Change in Cash stood at $41.9 million in 2022, then tumbled by 177.26% to -$32.4 million in 2023, then fell by 28.96% to -$41.7 million in 2024, then soared by 453.31% to $147.4 million in 2025, then slumped by 114.73% to -$21.7 million in 2026.
• According to Business Quant data, Change in Cash over the past three periods registered -$21.7 million, -$365000.0, and $147.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.